Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Sep 20, 2011, 05:57 ET from Reportlinker

NEW YORK, Sept. 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0617094/Macular-Degeneration-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Macular Degeneration Therapeutics market. The report identifies the key trends shaping and driving the global Macular Degeneration Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Macular Degeneration Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Macular Degeneration Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Macular Degeneration Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Macular Degeneration Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Macular Degeneration Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Macular Degeneration Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Macular Degeneration Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Macular Degeneration Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Macular Degeneration Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Macular Degeneration Therapeutics - Introduction 7

2.1 Disease Overview 7

2.1.1 Classification of AMD 7

2.1.2 Dry AMD 7

2.1.3 Wet AMD 8

2.2 Etiology and Pathophysiology 9

2.3 Epidemiology 10

2.3.1 Global 10

2.3.2 The US 10

2.3.3 The UK 10

2.3.4 Germany 10

2.3.5 Spain 10

2.3.6 Italy 10

2.3.7 France 10

2.3.8 Japan 10

2.3.9 Pharmaco-economic Burden 10

2.3.10 Quality of Life (QoL) 11

2.4 Signs and Symptoms 11

2.5 Diagnosis 12

2.5.1 History 12

2.5.2 Examination 12

2.6 Treatment and Management Pattern 14

2.6.1 Assessment and Treatment Plans for AMD 14

2.7 Referral Pathway 16

2.8 GlobalData Pipeline Report Guidance 17

3 Macular DegenerationTherapeutics - Market Characterization 18

3.1 Overview 18

3.2 Macular Degeneration Therapeutics Market Size 18

3.3 Macular Degeneration Therapeutics Market Size (2005-2010) - Global 19

3.4 Macular Degeneration Therapeutics Market Forecast (2010-2018) - Global 20

3.5 Macular Degeneration Therapeutics Market Size (2005-2010) - The US 21

3.6 Macular Degeneration Therapeutics Market Forecast (2010-2018) - The US 22

3.7 Macular Degeneration Therapeutics Market Size (2005-2010) - France 23

3.8 Macular Degeneration Therapeutics Market Forecast (2010-2018) - France 24

3.9 Macular Degeneration Therapeutics Market Size (2005-2010) - Germany 25

3.10 Macular Degeneration Therapeutics Market Forecast (2010-2018) - Germany 26

3.11 Macular Degeneration Therapeutics Market Size (2005-2010) - Italy 27

3.12 Macular Degeneration Therapeutics Market Forecast (2010-2018) - Italy 28

3.13 Macular Degeneration Therapeutics Market Size (2005-2010) - Spain 29

3.14 Macular Degeneration Therapeutics Market Forecast (2010-2018) - Spain 30

3.15 Macular Degeneration Therapeutics Market Size (2005-2010) - The UK 31

3.16 Macular Degeneration Therapeutics Market Forecast (2010-2018) - The UK 32

3.17 Macular Degeneration Therapeutics Market Size (2005-2010) - Japan 33

3.18 Macular Degeneration Therapeutics Market Forecast (2010-2018) - Japan 34

3.19 Drivers and Barriers for the Macular Degeneration Therapeutics Market 35

3.19.1 Drivers for the Macular Degeneration Therapeutics Market 35

3.19.2 Barriers for the Macular Degeneration Therapeutics Market 35

3.20 Opportunity and Unmet Need Analysis 35

3.21 Key Takeaway 36

4 Macular Degeneration Therapeutics - Competitive Assessment 37

4.1 Overview 37

4.2 Strategic Competitor Assessment 37

4.3 Product Profile for the Major Marketed Products in the AMD Therapeutics market 38

4.3.1 Lucentis (ranibizumab) 38

4.3.2 Visudyne (verteporfin) 39

4.3.3 Macugen (pegatanib sodium) 41

4.3.4 Avastin (bevacizumab) 42

4.4 Key Takeaway 42

5 Macular Degeneration Therapeutics - Pipeline Assessment 43

5.1 Overview 43

5.2 Strategic Pipeline Assessment 43

5.3 Macular Degeneration Therapeutics Pipeline - Pipeline by Phases of Development 43

5.3.1 Macular Degeneration Therapeutics - Phase III Pipeline 43

5.3.2 Macular Degeneration Therapeutics - Phase II Pipeline 44

5.3.3 Macular Degeneration Therapeutics - Phase I Pipeline 45

5.3.4 Macular Degeneration Therapeutics - Pre-clinical Pipeline 46

5.3.5 Macular Degeneration Therapeutics - Discovery Pipeline 47

5.4 Technology Trends Analytic Framework 48

5.5 Macular Degeneration Therapeutics Market - Pipeline by Mechanism of Action 49

5.6 Macular Degeneration Therapeutics - Promising Drugs Under Clinical Development 50

5.7 Molecule Profile for Promising Drugs under Clinical Development 50

5.7.1 Eylea (VEGF Trap-Eye) 50

5.8 Key Takeaway 51

6 Macular Degeneration Therapeutics - Clinical Trials Mapping 52

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 52

6.2 Clinical Trials by Phase 53

6.3 Clinical Trials by Trial Status 54

6.4 Prominent Sponsors 55

6.5 Top Companies Participating in Macular Degeneration Therapeutics Clinical Trials 56

7 Strategic Assessment 57

7.1 Key Events Impacting the Future Market 57

7.2 Future Market Competition Scenario 57

7.3 Macular Degeneration Therapeutics - Implications for Future Market Competition 58

8 Macular Degeneration Therapeutics - Future Players 59

8.1 Introduction 59

8.2 Company Profiles 59

8.2.1 Genentech /F. Hoffmann-La Roche 59

8.2.2 Bayer AG 62

8.2.3 Regeneron Pharmaceuticals, Inc. 65

8.3 Other Companies in AMD Therapeutics Market 66

9 Macular Degeneration Therapeutics - Licensing and Partnership Deals 70

10 Macular Degeneration Therapeutics - Appendix 72

10.1 Market Definitions 72

10.2 Abbreviations 72

10.3 Methodology 73

10.3.1 Coverage 73

10.3.2 Secondary Research 74

10.3.3 Forecasting 74

10.3.4 Primary Research 75

10.3.5 Expert Panel Validation 76

10.4 Contact Us 76

10.5 Disclaimer 76

10.6 Bibliography 76

List of Tables

Table 1: Treatment Recommendations and Follow-Up for Non-neovascular AMD 14

Table 2: Treatment Recommendations and Follow-Up for Neovascular AMD 15

Table 3: Macular Degeneration Therapeutics Market, Global, Revenue ($m), 2005-2010 19

Table 4: Macular Degeneration Therapeutics Market, Global, Forecast ($m), 2010-2018 20

Table 5: Macular Degeneration Therapeutics Market, the US, Revenue ($m), 2005-2010 21

Table 6: Macular Degeneration Therapeutics Market, the US, Forecast ($m), 2010-2018 22

Table 7: Macular Degeneration Therapeutics Market, France, Revenue ($m), 2005-2010 23

Table 8: Macular Degeneration Therapeutics Market, France, Forecast ($m), 2010-2018 24

Table 9: Macular Degeneration Therapeutics Market, Germany, Revenue ($m), 2005-2010 25

Table 10: Macular Degeneration Therapeutics Market, Germany, Forecast ($m), 2010-2018 26

Table 11: Macular Degeneration Therapeutics Market, Italy, Revenue ($m), 2005-2010 27

Table 12: Macular Degeneration Therapeutics Market, Italy, Forecast ($m), 2010-2018 28

Table 13: Macular Degeneration Therapeutics Market, Spain, Revenue ($m), 2005-2010 29

Table 14: Macular Degeneration Therapeutics Market, Spain, Forecast ($m), 2010-2018 30

Table 15: Macular Degeneration Therapeutics Market, the UK, Revenue ($m), 2005-2010 31

Table 16: Macular Degeneration Therapeutics Market, the UK, Forecast ($m), 2010-2018 32

Table 17: Macular Degeneration Therapeutics Market, Japan, Revenue ($m), 2005-2010 33

Table 18: Macular Degeneration Therapeutics Market, Japan, Forecast ($m), 2010-2018 34

Table 19: Macular Degeneration Therapeutics - Phase III Pipeline, 2011 43

Table 20: Macular Degeneration Therapeutics - Phase II Pipeline, 2011 44

Table 21: Macular Degeneration Therapeutics - Phase I Pipeline, 2011 45

Table 22: Macular Degeneration Therapeutics - IND Filing Pipeline, 2011 45

Table 23: Macular Degeneration Therapeutics- Pre-clinical Pipeline, 2011 46

Table 24: Macular Degeneration Therapeutics - Discovery Pipeline, 2011 47

Table 25: AMD Therapeutics - Most Promising Drugs Under Clinical Development, 2011 50

Table 26: Macular Degeneration Therapeutics - Clinical Trials by Country, 2011 52

Table 27: Macular Degeneration Therapeutics - Clinical Trials by Phase, 2011 53

Table 28: Macular Degeneration Therapeutics - Clinical Trials by Status, 2011 54

Table 29: Macular Degeneration Therapeutics - Prominent Sponsors, 2011 55

Table 30: Macular Degeneration Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 56

Table 31: F. Hoffman-La Roche - Ophthalmology Pipeline, 2011 60

Table 32: F. Hoffman-La Roche - Deals 2009-2010 61

Table 33: Bayer AG - AMD Pipeline, 2011 63

Table 34: Bayer AG Deals, 2009-2010 63

Table 35: Regeneron - AMD Pipeline, 2011 65

Table 36: Macular Degeneration Therapeutics Market - Future Players, 2011 66

Table 37: Macular Degeneration Therapeutics, Global, Deals, 2009-2011 70

List of Figures

Figure 1: Stages of Dry Age-Related Macular Degeneration 7

Figure 2: Classification of Age-Related Macular Degeneration 8

Figure 3: Stages of Age-related Macular Degeneration 9

Figure 4: Established And Possible Risk Factors-Age Related Macular Degeneration 11

Figure 5: The Amsler Grid Test 12

Figure 6: Optometric Management of the Patient with Age-related Macular Degeneration 14

Figure 7: Referral Pathway Age Related Macular Degeneration 16

Figure 8: Macular Degeneration Therapeutics Market, Global, Revenue ($m), 2005-2010 19

Figure 9: Macular Degeneration Therapeutics Market, Global, Forecast ($m), 2010-2018 20

Figure 10: Macular Degeneration Therapeutics Market, the US, Revenue ($m), 2005-2010 21

Figure 11: Macular Degeneration Therapeutics Market, the US, Forecast ($m), 2010-2018 22

Figure 12: Macular Degeneration Therapeutics Market, France, Revenue ($m), 2005-2010 23

Figure 13: Macular Degeneration Therapeutics Market, France, Forecast ($m), 2010-2018 24

Figure 14: Macular Degeneration Therapeutics Market, Germany, Revenue ($m), 2005-2010 25

Figure 15: Macular Degeneration Therapeutics Market, Germany, Forecast ($m), 2010-2018 26

Figure 16: Macular Degeneration Therapeutics Market, Italy, Revenue ($m), 2005-2010 27

Figure 17: Macular Degeneration Therapeutics Market, Italy, Forecast ($m), 2010-2018 28

Figure 18: Macular Degeneration Therapeutics Market, Spain, Revenue ($m), 2005-2010 29

Figure 19: Macular Degeneration Therapeutics Market, Spain, Forecast ($m), 2010-2018 30

Figure 20: Macular Degeneration Therapeutics Market, the UK, Revenue ($m), 2005-2010 31

Figure 21: Macular Degeneration Therapeutics Market, the UK, Forecast ($m), 2010-2018 32

Figure 22: Macular Degeneration Therapeutics Market, Japan, Revenue ($m), 2005-2010 33

Figure 23: Macular Degeneration Therapeutics Market, Japan, Forecast ($m), 2010-2018 34

Figure 24: Opportunity and Unmet Need in the Macular Degeneration Therapeutics Market 36

Figure 25: Strategic Competitor Assessment of the Major Marketed Products in AMD, 2011 37

Figure 26: Clinical Study Details - Lucentis 38

Figure 27: Clinical Study Details - Visudyne 40

Figure 28: Clinical Study Details - Macugen 41

Figure 29: Macular Degeneration Therapeutics - Pipeline by Phase of Development, 2011 43

Figure 30: Macular Degeneration Therapeutics - Technology Trends Analytics Framework, 2011 48

Figure 31: Macular Degeneration Therapeutics - Technology Trends Analytics Framework - Description, 2011 48

Figure 32: Macular Degeneration Therapeutics - Pipeline by Mechanism of Action, 2011 49

Figure 33: Clinical Study Details - VEGF Trap-Eye 50

Figure 34: Macular Degeneration Therapeutics - Clinical Trials by Country, 2011 52

Figure 35: Macular Degeneration Therapeutics - Clinical Trials by Phase, 2011 53

Figure 36: Macular Degeneration Therapeutics - Clinical Trials by Status, 2011 54

Figure 37: Macular Degeneration Therapeutics - Overall Sponsors, 2011 55

Figure 38: Macular Degeneration Therapeutics - Prominent Sponsors, 2011 55

Figure 39: Macular Degeneration Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 56

Figure 40: Key Events Competition in the Macular Degeneration Therapeutics Market, 2011 57

Figure 41: Implications for Future Market Competition in the Macular Degeneration Market, 2011 58

Figure 42: Macular Degeneration Therapeutics Market - Pipeline by Company, 2011 59

Companies Mentioned

Genentech /F. Hoffmann-La Roche

Bayer AG

Regeneron Pharmaceuticals, Inc.

To order this report:

Drug Discovery and Development Industry: Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Drug Discovery and Development Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com